Lunit Inc. (KRX: 328130) develops and provides artificial intelligence-powered software solutions for cancer screening, diagnostics, and therapeutics. The company offers Lunit INSIGHT CXR for chest X-ray analysis; Lunit INSIGHT MMG for 2D mammography; Lunit INSIGHT DBT for digital breast tomosynthesis; Lunit SCOPE for biomarker analysis including immune phenotyping, PD-L1 quantification, and genotype prediction; and Lunit CXR Triage for emergency department chest X-ray prioritization. These FDA-cleared solutions support medical imaging, pathology, and precision oncology across over 4,800 institutions in more than 55 countries. Founded in 2013 and headquartered in Seoul, South Korea, Lunit operates globally with offices in Boston, Massachusetts, and Amsterdam, Netherlands, targeting healthcare providers, radiologists, and biopharma partners. In 2024, Lunit completed its US$193 million acquisition of Volpara Health Technologies, enhancing breast cancer screening capabilities and expanding U.S. market presence to over 200 imaging centers by mid-2025, surpassing 1 million mammograms analyzed. Recent strategic collaborations include a November 2025 partnership with Labcorp for AI-powered digital pathology; an alliance with AstraZeneca on Lunit SCOPE Genotype Predictor for NSCLC mutation analysis; and supply agreements with GE Healthcare, Philips, and Akumin for 3D breast imaging solutions, driving record H1 2025 revenue of KRW 37.1 billion.